Analyse NeuroPace, Inc. (NPCE) — Kairos Score 65/100

À propos de NeuroPace, Inc.

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

Informations clés

🕴️ Activité des initiés (90 jours)

5 transactions — 0 achats et 0 ventes déclarés par les dirigeants de NeuroPace, Inc..

🏦 Hedge Funds

16 fonds institutionnels déclarent une position sur NPCE dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur NPCE.

• Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report?
• Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.